It Takes a Village:

Collaborating to make a difference in the lives of people with bladder cancer

 

Despite new discoveries and improvements in the care of people with bladder cancer, there's still a significant need for scientific advancement in this area. At Merck, we have made it our mission to help address this need through innovative research.

Bladder cancers are divided into various types depending on the type of cells that become cancerous. The most common type is urothelial (transitional cell) carcinoma, which most often starts in the urothelial cells lining the inside of the bladder. Bladder cancers can also be characterized as “invasive” or “non-invasive” depending on how far they have spread into the wall of the bladder. Non-muscle invasive bladder cancer occurs when the cancer has not grown into the main muscle layer of the bladder.

If not caught early enough, bladder cancer can become invasive and spread to other organs, sometimes leading to a radical cystectomy (bladder removal).

Our bladder cancer team has dedicated itself to researching the unmet needs of patients. Working across functions - and continents - the team has worked tirelessly and collaboratively to uncover solutions and help patients with bladder cancer.

We invited members of the team to share perspective on what drives them to deliver on Merck’s mission.

Ekta Kapadia, MD
director
Clinical Research Oncology

As an oncologist, I’ve had the privilege of caring for many patients with cancer. Their courage inspires me to do all I can to help advance research to find new approaches to improving and prolonging lives. Making progress against bladder cancer takes vision, collaboration and perseverance – and I’m proud to be part of a team that’s driving research forward to help people facing this disease.

Jeffrey N. Stuart, Ph.D., RAC
executive director
Global Regulatory Affairs

We put patients at the center of everything we do. Our vision focuses on collaboration and empowerment to achieve global regulatory milestones. We do this through strong strategic acumen, high quality documentation, and timely deliverables. As a high-performing global regulatory team that frequently integrates diverse styles, ideas and perspectives, we champion courage and flexibility to do what is best for patients on the front lines of fighting cancer.